Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

71.07USD
1:30am IST
Change (% chg)

$-0.45 (-0.63%)
Prev Close
$71.52
Open
$71.69
Day's High
$71.76
Day's Low
$70.83
Volume
2,411,073
Avg. Vol
2,416,546
52-wk High
$89.53
52-wk Low
$64.27

Select another date:

Wed, Jun 20 2018

GSK takes billion-dollar drug fight with Gilead to top AIDS meeting

LONDON, June 20 GlaxoSmithKline is taking its fight with Gilead Sciences for dominance of the HIV market to the world's leading AIDS conference next month by showcasing detailed results from its new two-drug treatment.

GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

June 14 GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field.

BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018

* GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Gilead Sciences Reports Q1 EPS $1.17

* GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

UPDATE 1-Gilead hepatitis C drug sales slump, shares fall 5 pct

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.

Gilead hepatitis C drug sales slump, shares fall 6 percent

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down nearly 6 percent.

BRIEF-Gilead And Verily Announce Scientific Collaboration

* GILEAD AND VERILY ANNOUNCE SCIENTIFIC COLLABORATION TO IDENTIFY AND UNDERSTAND IMMUNOLOGICAL AND MOLECULAR DRIVERS OF INFLAMMATORY DISEASES

Gilead's three-drug HIV regimen wins European panel approval

Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

Gilead's three-drug HIV regimen wins European panel approval

April 27 Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

Select another date: